myc-in-2

MYC-IN-2 is a protein-protein inhibitor targeting the MYC protein, designed for use in cancer research.

Puromycin dihydrochloride (CL13900 dihydrochloride) 属于肉桂酰胺腺苷抗生素，是一种蛋白质合成的抑制剂。Puromycin dihydrochloride 通过与 RNA 结合来抑制蛋白质合成，具有抗肿瘤和抗锥虫活性。

6-fluorinated-aristeromycin2c 具有抗病毒感染活性，对热病毒、寨卡病毒和Sars 冠状病毒具有抑制作用。

Erythromycin 2'-propionate is a macrolide antibiotic and an esterified form of erythromycin .1It is active againstS. aureuswhen used at a concentration of 1 μg/ml. Erythromycin 2'-propionate (1 mM) inhibits protein synthesis in a cell-free assay. 1.Tardrew, P.L., Mao, J.C.H., and Kenney, D.Antibacterial activity of 2'-esters of erythromycinAppl. Microbiol.18(2)159-165(1969)

Arlacel A 一种在生化反应中使用的试剂。

Idarubicin 是一种有效的、具有口服活性的蒽环类抗白血病剂。Idarubicin 抑制拓扑异构酶 II，干扰 DNA 复制和 RNA 转录。Idarubicin 可诱导 DNA 损伤。Idarubicin 抑制 DNA 合成和 c-myc 表达。Idarubicin 还抑制细菌和酵母菌的生长。

CBP EP300-IN-2 is an inhibitor of CBP EP300 (IC50s: 1.07 nM and 5.96 nM for CBP HTRF and Myc).

LZZ-02通过稳定axin 2并减少包括c-Myc和cyclin D1在内的下游蛋白水平，降解β-catenin的表达，从而抑制β-catenin的转录活性，有效缩小源自结肠细胞系的肿瘤异种移植物。

FTO-IN-13 (compound 8t) 是一种有效的FTO抑制剂，具备抗增殖和抗癌活性。该化合物能够诱导细胞凋亡 (apoptosis)，并降低Bcl-2和Caspase 3活性蛋白的表达，同时抑制MYC和CEBPA基因的表达。

HDAC3 BRD4-IN-1 (compound 26n) 是一种HDAC3 BRD4的抑制剂，其针对HDAC3的IC50为8 nM，而对HDAC1和HDAC2的IC50分别为220 nM和120 nM。HDAC3 BRD4-IN-1 展现出抗肿瘤和抗增殖作用，并通过上调Ac-H3和下调c-Myc实现。该化合物在人肝脏微粒中的半衰期为29.36分钟 (t1 2=29.36 min)。

PROTAC BRD4 Degrader-8 is a potent BRD4 inhibitor, with IC50s of 1.1 nM and 1.4 nM for BRD4 BD1 and BD2, respectively. PROTAC BRD4 Degrader-8 is capable of potently degrading the BRD4 protein in PC3 prostate cancer cells[1]. PROTAC BRD4 Degrader-8 (compound 8; 6 days) inhibits the proliferation of PC3 prostate cancer cells, with an IC50 of 28 nM[1].PROTAC BRD4 Degrader-8 (4 h) suppresses MYC gene transcript in MV4-11 AML cells, with an IC50 of 11 nM[1].PROTAC BRD4 Degrader-8 (4 h) potently degrades the BRD4 protein in PC3 prostate cancer cells, with an DC50 of 7.5 nM[1]. [1]. Dragovich PS, et, al. Antibody-Mediated Delivery of Chimeric BRD4 Degraders. Part 2: Improvement of In Vitro Antiproliferation Activity and In Vivo Antitumor Efficacy. J Med Chem. 2021 Mar 11;64(5):2576-2607.

Nemorosone is a polycyclic polyprenylated acylphloroglucinol (PPAP) originally isolated from C. rosea that has antiproliferative properties.1 Nemorosone inhibits growth of NB69, Kelly, SK-N-AS, and LAN-1 neuroblastoma cells (IC50s = 3.1-6.3 μM), including several drug-resistant clones, but not MRC-5 human embryonic fibroblasts (IC50 = >40 μM).2 It increases DNA fragmentation in LAN-1 cells in a dose-dependent manner, and decreases N-Myc protein levels and phosphorylation of ERK1 2 by MEK1 2. Nemorosone also inhibits growth of Capan-1, AsPC-1, and MIA-PaCa-2 pancreatic cancer cells (IC50s = 4.5-5.0 μM following a 72-hour treatment) but not human dermal and foreskin fibroblasts (IC50s = >35 μM).1 It induces apoptosis, abolishes the mitochondrial membrane potential, and increases cytosolic calcium concentration in pancreatic cancer cells in a dose-dependent manner. Nemorosone activates the caspase cascade in a dose-dependent manner and inhibits cell cycle progression, increasing the proportion of cells in the G0 G1 phase, in both neuroblastoma and pancreatic cancer cells.1,2 Nemorosone (50 mg kg, i.p., per day) also reduces tumor growth in an MIA-PaCa-2 mouse xenograft model.3References1. Holtrup, F., Bauer, A., Fellenberg, K., et al. Microarray analysis of nemorosone-induced cytotoxic effects on pancreatic cancer cells reveals activation of the unfolded protein response (UPR). Br. J. Pharmacol. 162(5), 1045-1059 (2011).2. Díaz-Carballo, D., Malak, S., Bardenheuer, W., et al. Cytotoxic activity of nemorosone in neuroblastoma cells. J. Cell. Mol. Med. 12(6B), 2598-2608 (2008).3. Wold, R.J., Hilger, R.A., Hoheisel, J.D., et al. In vivo activity and pharmacokinetics of nemorosone on pancreatic cancer xenografts. PLoS One 8(9), e74555 (2013). Nemorosone is a polycyclic polyprenylated acylphloroglucinol (PPAP) originally isolated from C. rosea that has antiproliferative properties.1 Nemorosone inhibits growth of NB69, Kelly, SK-N-AS, and LAN-1 neuroblastoma cells (IC50s = 3.1-6.3 μM), including several drug-resistant clones, but not MRC-5 human embryonic fibroblasts (IC50 = >40 μM).2 It increases DNA fragmentation in LAN-1 cells in a dose-dependent manner, and decreases N-Myc protein levels and phosphorylation of ERK1 2 by MEK1 2. Nemorosone also inhibits growth of Capan-1, AsPC-1, and MIA-PaCa-2 pancreatic cancer cells (IC50s = 4.5-5.0 μM following a 72-hour treatment) but not human dermal and foreskin fibroblasts (IC50s = >35 μM).1 It induces apoptosis, abolishes the mitochondrial membrane potential, and increases cytosolic calcium concentration in pancreatic cancer cells in a dose-dependent manner. Nemorosone activates the caspase cascade in a dose-dependent manner and inhibits cell cycle progression, increasing the proportion of cells in the G0 G1 phase, in both neuroblastoma and pancreatic cancer cells.1,2 Nemorosone (50 mg kg, i.p., per day) also reduces tumor growth in an MIA-PaCa-2 mouse xenograft model.3 References1. Holtrup, F., Bauer, A., Fellenberg, K., et al. Microarray analysis of nemorosone-induced cytotoxic effects on pancreatic cancer cells reveals activation of the unfolded protein response (UPR). Br. J. Pharmacol. 162(5), 1045-1059 (2011).2. Díaz-Carballo, D., Malak, S., Bardenheuer, W., et al. Cytotoxic activity of nemorosone in neuroblastoma cells. J. Cell. Mol. Med. 12(6B), 2598-2608 (2008).3. Wold, R.J., Hilger, R.A., Hoheisel, J.D., et al. In vivo activity and pharmacokinetics of nemorosone on pancreatic cancer xenografts. PLoS One 8(9), e74555 (2013).

BRD4 Inhibitor-15 (compound 13) is a highly potent and specific inhibitor of BRD4, effectively inhibiting it with an IC50 of 18 nM. By regulating the Bcl-2 Bax proteins and activating the caspase-3 signaling pathway, BRD4 Inhibitor-15 induces apoptosis of 22RV1 cells. Additionally, it effectively down-regulates the c-Myc level in 22RV1 cells. Due to its properties, BRD4 Inhibitor-15 is a valuable compound for research related to prostate cancer [1].

P300 bromodomain-IN-1 是 p300 (EP300) bromodomain 的有效抑制剂 (IC50: 49 nM)。P300 bromodomain-IN-1 能够阻碍 c-Myc 的表达，并诱导 OPM-2 细胞的细胞周期阻滞在 G1 G0 期及诱导其凋亡 (apoptosis)。

MRK003 is a γ-secretase inhibitor exhibits promising in vitro pre-clinical activity in multiple myeloma and non-Hodgkin's lymphoma. MRK003 treatment induced caspase-dependent apoptosis and inhibited proliferation of MM and NHL cell lines and patient cells. Examination of signaling events after treatment showed time-dependent decrease in levels of the notch intracellular domain, Hes1 and c-Myc. MRK003 downregulated cyclin D1, Bcl-Xl and Xiap levels in NHL cells and p21, Bcl-2 and Bcl-Xl in MM cells. In addition, MRK003 caused an upregulation of pAkt, indicating crosstalk with the PI3K Akt pathway.

eIF4A3-IN-18 是silvestrol 类似物。eIF4A3-IN-18 干扰eIF4F 翻译复合体组装，对 myc-LUC，tub-LUC 和抑制 MBA-MB-231 细胞生长的EC50值分别为 0.8、35 和 2 nM。eIF4A3-IN-18 对 RMPI-8226 细胞具有细胞毒性，LC50值为 0.06 nM。eIF4A3-IN-18 可用于人类肿瘤发病机制的研究。

FUBP1-IN-2 是一种有效的 FUBP1(远上游结合蛋白 1) 抑制剂。在凝胶移位试验中，FUBP1-IN-2 抑制 KH4 FUBP1-FUSE 相互作用。FUBP1-IN-2 在 ChIP 试验中与 FUBP1 结合。FUBP1-IN-2 可降低 c-MycmRNA 和蛋白表达，增加 p21mRNA 和蛋白表达，并消耗细胞内多胺。

USP28-IN-2是一种高选择性的USP28抑制剂(IC50=0.3 μM)，能够特异性作用于USP2、USP7、USP8、USP9x、UCHL3 和 UCHL5。在体外实验中，USP28-IN-2对癌细胞表现出细胞毒性，作用机制为通过泛素-蛋白酶体途径降低c-Myc蛋白水平，并能减少Ankyrase-1 2的表达。此外，USP28-IN-2能增强结直肠癌细胞对药物瑞戈非尼的敏感性。

Tat-QFNP12 是一种含有转录激活因子 (Tat) 跨膜结构域和抑制N-Myc下游调节基因2 (NDRG2) 与蛋白磷酸酶Mg2+/Mn2+依赖性1A (PPM1A) 蛋白-蛋白相互作用的肽。在以20 mg/kg剂量给药的内脑血管穿刺诱导的小鼠蛛网膜下腔出血模型中，它能减少由基质金属蛋白酶-9 (MMP-9) 浓度增高引起的血脑屏障内皮紧密连接的损失，减轻脑水肿，并且提高自发活动及肢体运动的对称性。

MGH-CP1 是 TEAD2 (IC50:710 nM) 及 TEAD4 (IC50:672 nM) 自棕榈酰化抑制剂，口服有活性，可降低细胞内源性或异位表达的 TEAD 蛋白棕榈酰化水平。MGH-CP1 与 Lats1 2 缺失，是 Myc 的表达受到抑制，阻碍上皮细胞过度增殖，诱导细胞凋亡。

Moracin treatment can inhibit the double 12-O-tetradecanoylphorbol 13-acetate (TPA) treatment-induced morphological changes reflecting inflammatory response, including leucocyte infiltration, hyperplasia and cell proliferation; moracin treatment furthermo